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Abstract
Background: Previous studies demonstrate that tolterodine extended release (ER) significantly improves
urgency urinary incontinence (UUI) episodes. Instruments that measure patient-reported outcomes
(PROs) provide additional information that is valuable for assessing whether clinical improvements are
meaningful to the patient. This study determined the correlation of changes in bladder diary variables and
other PROs in subjects with overactive bladder (OAB).
Methods: Subjects with OAB, urinary frequency, and UUI were treated with 4 mg once-daily tolterodine
ER or placebo for 12 weeks. Subjects completed 7-day bladder diaries, the Patient Perception of Bladder
Condition (PPBC), and the King's Health Questionnaire (KHQ) at baseline and week 12. Only subjects
who reported at least some minor bladder-related problems at baseline (PPBC score ≥ 3) were included
in this analysis.
Results: Reductions in UUI episodes per week were significantly greater in the tolterodine ER group (n
= 500) compared with the placebo group (n = 487) at week 12 (-71% vs -33%, P < 0.0001). A significantly
greater percentage of subjects in the tolterodine ER group reported improvement on the PPBC versus
placebo (58% vs 45%, P < 0.0001), and 7 of 10 KHQ domains were significantly improved versus placebo
(all P < 0.05). Significant correlations were found for median percentage changes in UUI episodes with
changes in PPBC scores (r = 0.35,P < 0.0001) and the 7 improved KHQ domains (r = 0.16–0.32, P ≤
0.0011). Changes in PPBC scores and all KHQ domains were significantly correlated (r = 0.13–0.38, P ≤
0.009) in the tolterodine ER group. Correlations among endpoints in the placebo group were similar to
those observed in the tolterodine ER group.
Conclusion: Improvement in UUI episodes after 12 weeks of treatment with tolterodine ER or placebo
was correlated with improvements in patients' perception of their bladder-related problems and health-
related quality of life. Correlations were moderate in magnitude but statistically significant, suggesting that
PROs are important and relevant measures for evaluating OAB treatment.
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Background
Overactive bladder (OAB) is defined by the International
Continence Society (ICS) as urgency, with or without
urgency urinary incontinence (UUI), usually with
increased daytime frequency and nocturia [1,2]. OAB
affects approximately 17% of adults in the United States
[3] and Europe [4]. A recent study using current ICS defi-
nitions of OAB found the prevalence of OAB to be 11% in
men and 13% in women [5]. It was also demonstrated
that the prevalence of OAB increases with advancing age,
occurring in 20% of subjects who are ≥ 60 years of age.
Antimuscarinics, such as tolterodine, are first-line treat-
ments for OAB and have proven efficacy and tolerability
[6].
Bladder diaries are traditionally used to quantify OAB
symptoms and provide information about treatment
effects on the frequency and severity of symptoms, but
they do not provide information regarding the patient's
perspective on his or her symptoms or the impact of treat-
ment. Instruments that measure patient-reported out-
comes (PROs) provide valuable additional information
for assessing whether clinical improvements are meaning-
ful to the patient [7]. Several questionnaires, measuring a
broad array of concepts, have been validated for use in
subjects with OAB, including the King's Health Question-
naire (KHQ) [8] and Patient Perception of Bladder Condi-
tion (PPBC) [9].
Numerous studies have used questionnaires to demon-
strate that OAB symptoms have a negative impact on the
subjects' health-related quality of life (HRQL) [3,10-13].
OAB adversely affects social and professional activities,
social and sexual relationships, and travel [14,15]. Treat-
ment with antimuscarinics is associated with significant
improvement in HRQL, symptom bother, and perception
of treatment benefit, as well as improvement in bladder
diary variables [16-19]. Evidence suggests that treatment
effects on the number and/or severity of OAB symptoms
and urodynamic variables may not be fully predictive of
treatment effects on HRQL and other PROs that are not
based on changes in bladder diary variables, leading some
authors to advocate that the use of these PROs become
standard in clinical studies of OAB [20].
We evaluated the relationships between treatment-related
changes in UUI episodes as recorded in bladder diaries
and 2 validated questionnaires using data from a large
placebo-controlled trial of tolterodine [21].
Methods
Details of the study design have been previously pub-
lished [21]. Briefly, this 12-week, double-blind, placebo-
controlled trial included subjects with urinary frequency
(≥ 8 micturitions per 24 h) and UUI (≥ 5 episodes per wk)
who had OAB symptoms for ≥ 6 months. This study was
conducted in 167 centers in Australasia (n = 4), Europe (n
= 89), and North America (n = 74). The study was con-
ducted in accordance with the Good Clinical Practice
Guidelines and the Declaration of Helsinki. The appropri-
ate International Ethics Committees/Institutional Review
Boards approved the study protocol, and all patients gave
written informed consent before the start of the study.
Subjects were randomized to once-daily treatment with 4
mg tolterodine extended release (ER) or placebo for 12
weeks. For this analysis, only subjects who reported at
least some minor bladder-related problems at baseline
(PPBC score ≥ 3) were included.
Symptom assessment using bladder diaries and 
questionnaires
Subjects completed 7-day bladder diaries in which they
recorded every incontinence episode, urgency episode,
and micturition at the times at which they occurred during
7 consecutive days prior to the baseline and week 12 vis-
its. Subjects also completed the KHQ and the PPBC at
baseline and week 12. The KHQ is a measure of HRQL
that includes 2 single-item domains (General Health Per-
ceptions and Incontinence Impact), 7 multi-item
domains (Role Limitations, Physical Limitations, Social
Limitations, Personal Relationships, Emotions, Sleep/
Energy, Severity/Coping), and a multi-item Symptom
Severity scale [22]. The 2 single-item domains and the 7
multi-item domains of the KHQ are scored on a scale
from 0 (best) to 100 (worst). The Symptom Severity scale
is scored from 0 (best) to 30 (worst). Decreases in KHQ
domain scores indicate an improvement in HRQL. The
minimally important difference (MID) – the smallest
change in score that subjects perceive as beneficial – is 3
points for the Symptom Severity scale and 5 points for all
other KHQ domains [23].
The PPBC is a validated single-item measure of the sub-
jects' perception of the extent of their bladder-related
problems [9,24]. Subjects select 1 of 6 statements ranging
from "my bladder condition does not cause me any prob-
lems at all" to "my bladder condition causes me many
severe problems" [9,24]. A decrease in score indicates
improvement.
Statistical analysis
Median percentage changes in UUI episodes per week
were analyzed using a rank analysis of covariance
(ANCOVA) with baseline value as a covariate; mean
changes in UUI episodes per week were analyzed using
ANCOVA with baseline value as a covariate. Mean
changes in KHQ scores from baseline to week 12 were
analyzed for the current study using ANCOVA with base-
line value as a covariate. Categorical changes in PPBC
scores were analyzed using chi-square tests. A ≥ 2-pointHealth and Quality of Life Outcomes 2009, 7:13 http://www.hqlo.com/content/7/1/13
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reduction in PPBC score was considered a major improve-
ment, a 1-point reduction was considered a minor
improvement, and no change or an increase was consid-
ered no improvement in the extent of bladder-related
problems. The relationships between changes in UUI epi-
sodes, PPBC scores, and KHQ scores were evaluated using
Spearman correlation coefficients. Changes in UUI epi-
sodes were used for this analysis because they were a
defining symptom for this population. Correlations were
considered to be small in size for |r| < 0.30 and moderate
in size for |r| = 0.30 to 0.49 [25].
Results
Baseline demographics and clinical characteristics for 987
subjects (placebo, n = 487; tolterodine ER, n = 500) are
presented in Table 1. Most subjects were women (82%)
and white (95%).
Subjects treated with tolterodine ER showed a signifi-
cantly greater median percentage (-71% vs -33%, P  <
0.0001) and mean (-11.8 vs -6.9, P < 0.0001) reduction in
UUI episodes per week than did subjects treated with pla-
cebo. A significantly greater percentage of subjects treated
with tolterodine ER showed improvement in PPBC scores
(58%; 30% with ≥ 2-point improvement) than did sub-
jects treated with placebo (45%; 21% with ≥ 2-point
improvement; P < 0.0001). Subjects treated with tolterod-
ine ER also achieved significantly larger improvements on
7 KHQ domains, including Incontinence Impact, Role
Limitations, Physical Limitations, Social Limitations,
Sleep/Energy, Severity/Coping, and Symptom Severity
compared with subjects receiving placebo (Table 2).
Among subjects treated with tolterodine ER, the change in
every KHQ domain score except Symptom Severity and
General Health Perceptions exceeded MID criteria for
improvement [23]. The MID criteria were met for the
Emotions domain in the tolterodine ER group; however,
the improvement from baseline was not statistically sig-
nificant (P = 0.0746) compared with the placebo group.
Among subjects receiving tolterodine ER, the present anal-
ysis revealed a moderately sized but statistically signifi-
cant correlation between week 12 median percentage
reductions in UUI episodes and changes in PPBC score
(|r| ≥ 0.35, P ≤ 0.001). Small to moderately sized but sta-
tistically significant correlations were also observed
between median percentage reductions in UUI episodes
from baseline and improvements in 8 of 10 KHQ
domains (|r| = 0.16–0.35, all P ≤ 0.01) in tolterodine ER-
treated subjects (Table 3). Similar correlations were
observed between mean reductions in UUI episodes and
improvements in PPBC and KHQ scores.
Treatment-related changes in PPBC scores were correlated
with changes in all 10 KHQ domains (Table 4). Similar
relationships were observed in the placebo group. Moder-
ate but statistically significant correlations (|r| ≥ 0.30, all
P  < 0.001) were observed between PPBC scores and
Incontinence Impact, Role Limitations, Physical Limita-
tions, Emotions, Severity/Coping, and Symptom Severity
in the tolterodine ER group; the placebo group showed
similar correlations except for Emotions and Symptom
Severity, which were poorly correlated. Categorical
improvement on the PPBC was correlated with improve-
ments in KHQ domain scores in the tolterodine ER group
(Figure 1). Changes in KHQ scores were 2 to 3 times larger
Table 1: Baseline demographic and clinical characteristics
Characteristic Placebo
(n = 487)
TER
(n = 500)
Women, n (%) 401 (82) 412 (82)
Age,* y 61 (14) 60 (14)
Range 22–93 20–89
Race, n (%)
White 460 (95) 477 (95)
Black 19 (4) 17 (3)
Other 8 (2) 6 (1)
UUI episodes per wk* 23.5 (20.7) 22.3 (22.4)
Micturitions per 24 h* 11.3 (3.8) 10.9 (4.2)
Volume voided per micturition,* mL 135.3 (41.9) 140.1 (42.7)
TER = tolterodine extended release; UUI = urgency urinary 
incontinence.
*Data are mean (SD).
Table 2: Change from baseline to week 12 in KHQ domain 
scores by treatment group
KHQ Domain Placebo
Mean (SD)
[n]
TER
Mean (SD)
[n]
P Value
General Health Perceptions -0.06 (17.4)
[406]
-0.4 (17.6)
[419]
0.9850
Incontinence Impact -8.9 (26.7)
[405]
-16.0 (29.4)
[417]
<0.0001
Role Limitations -10.4 (29.3)
[404]
-18.1 (30.7)
[416]
<0.0001
Physical Limitations -9.0 (28.1)
[404]
-15.8 (30.1)
[417]
0.0003
Social Limitations -6.3 (22.8)
[402]
-8.7 (23.4)
[411]
0.0431
Personal Relationships -3.5 (23.2)
[265]
-5.8 (27.0)
[259]
0.4759
Emotions -6.4 (24.1)
[403]
-9.4 (25.0)
[413]
0.0746
Sleep/Energy -4.8 (21.0)
[404]
-9.9 (24.6)
[415]
0.0033
Severity/Coping -6.1 (20.0)
[402]
-11.9 (22.1)
[414]
<0.0001
Symptom Severity -1.5 (3.9)
[406]
-2.9 (4.1)
[419]
<0.0001
KHQ = King's Health Questionnaire; TER = tolterodine extended 
release.Health and Quality of Life Outcomes 2009, 7:13 http://www.hqlo.com/content/7/1/13
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in subjects who showed a ≥ 2-point improvement on the
PPBC than in those who showed a 1-point improvement.
There were improvements from baseline in UUI episodes,
PPBC, and KHQ in the placebo group that were statisti-
cally significantly smaller than those in the tolterodine ER
group (Table 2). However, correlations among these end-
points in the placebo group were similar to those
observed in the tolterodine ER group (Tables 3 and 4).
Discussion
In this analysis, the tolterodine ER group showed statisti-
cally significant and clinically meaningful improvements
in UUI episodes, subjects' perceptions of the extent of
their bladder-related problems, and HRQL compared
with placebo. These results are consistent with previous
reports demonstrating that tolterodine ER significantly
improved UUI episodes [26,27], PPBC scores [18,26], and
KHQ scores [16,17] in subjects with OAB. However, cor-
relational analyses showed that improvement in UUI epi-
sodes was significantly correlated with improvements in
PPBC scores and most domains of the KHQ in subjects
receiving either tolterodine ER or placebo. The results
were similar regardless of whether median percentage or
mean changes in UUI episodes were used in the analyses.
Changes in PPBC scores were also correlated with changes
in scores on each domain of the KHQ, and categorical
improvements in PPBC scores were positively associated
with the magnitude of improvement on each KHQ
domain. These data suggest that the PPBC and KHQ are
relevant measures of OAB treatment efficacy.
Although the correlations among improvements in UUI
episodes, PPBC scores, and KHQ scores after treatment
with tolterodine ER were small to moderate, they were sta-
tistically significant. Similarly, a study that used data from
primary care patients collected during an open-label trial
of tolterodine ER found that improvements in bladder
diary variables were significantly correlated with improve-
ments on the PPBC, the Overactive Bladder Questionnaire
(OAB-q) Symptom Bother scale, and all HRQL domains
of the OAB-q [28]. As in the present study, the correlations
were small to moderate but statistically significant. Col-
lectively, these findings suggest that PROs provide infor-
mation about OAB treatment efficacy that is related to,
but not redundant with, bladder diaries. This interpreta-
tion is consistent with a study by Abrams et al [20] in
which symptom-based outcomes (ie, bladder diaries, uro-
dynamics) were compared with questionnaire outcomes
from 27 clinical trials of antimuscarinics. The results
showed that, although there were often parallel improve-
ments in these 2 outcomes, there were cases in which
improvements in symptom-based measures were not
accompanied by corresponding changes in PRO meas-
ures.
Abrams et al [20] concluded that statistically significant
changes in the frequency of symptoms may not always
reflect subjects' assessments of treatment success, and that
both symptom-based measures and patient-centric meas-
ures of treatment impact should be used in studies of OAB
pharmacotherapy [20]. The findings reported here sup-
port the conclusion that symptom-based measures and
patient-centric measures are complementary and should
be used together in clinical trials. The KHQ, PPBC, and
other instruments, such as the OAB-q, Overactive Bladder
Symptom Score (OABSS) and Urgency Perception Scale
(UPS), have been validated among patients with OAB and
are reliable and responsive to treatment [9,10,24,29-32].
Table 3: Correlations between percentage change from baseline 
in UUI episodes and changes in PPBC and KHQ domain scores in 
subjects treated with TER or placebo
Placebo TER
rP   Value rP   Value
PPBC 0.32 <0.0001 0.35 <0.0001
KHQ domain
General Health Perceptions 0.11 0.0252 0.09 0.0687
Incontinence Impact 0.27 <0.0001 0.32 <0.0001
Role Limitations 0.30 <0.0001 0.16 0.0008
Physical Limitations 0.25 <0.0001 0.23 0.0001
Social Limitations 0.13 0.0078 0.16 0.0011
Personal Relationships 0.12 0.0436 0.11 0.0773
Emotions 0.14 0.0041 0.25 <0.0001
Sleep/Energy 0.24 <0.0001 0.19 0.0001
Severity/Coping 0.34 <0.0001 0.30 <0.0001
Symptom Severity 0.33 <0.0001 0.32 <0.0001
KHQ = King's Health Questionnaire; PPBC = Patient Perception of 
Bladder Condition; TER = tolterodine extended release; UUI = 
urgency urinary incontinence.
Table 4: Correlations between PPBC and KHQ domain change 
scores in subjects treated with TER or placebo
Placebo TER
KHQ Domain rP   Value rP   Value
General Health Perceptions 0.14 0.0038 0.13 0.009
Incontinence Impact 0.41 <0.0001 0.36 <0.0001
Role Limitations 0.31 <0.0001 0.31 <0.0001
Physical Limitations 0.35 <0.0001 0.33 <0.0001
Social Limitations 0.29 <0.0001 0.24 <0.0001
Personal Relationships 0.16 0.0113 0.17 0.0076
Emotions 0.25 <0.0001 0.30 <0.0001
Sleep/Energy 0.22 <0.0001 0.20 <0.0001
Severity/Coping 0.36 <0.0001 0.33 <0.0001
Symptom Severity 0.30 <0.0001 0.38 <0.0001
KHQ = King's Health Questionnaire; PPBC = Patient Perception of 
Bladder Condition; TER = tolterodine extended release.Health and Quality of Life Outcomes 2009, 7:13 http://www.hqlo.com/content/7/1/13
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In the current study, correlations between improvements
in PPBC and KHQ scores were also of small to moderate
strength, suggesting that these instruments may reflect dif-
ferent aspects of OAB treatment efficacy. The PPBC, a sin-
gle-item measure that is easy to use and interpret, provides
a global integrated measure of the subjects' perception of
the extent of their bladder-related problems. Other vali-
dated instruments, such as the KHQ or OAB-q, provide
detailed and multidimensional information concerning
patient outcome or condition that is not captured by a sin-
gle-item measure. The choice of questionnaires adminis-
tered in clinical trials should reflect the research objectives
of the trial [9].
Notably, these instruments are patient-friendly and may
help clinicians diagnose OAB and assess treatment effi-
cacy in the clinic without the inconvenience of a bladder
diary. The importance of measuring patients' assessment
of treatment impact has been demonstrated by evidence
of disparity between the opinions of clinicians and
patients regarding the level of bother and the impact of
urinary symptoms on HRQL [33].
Although changes from baseline for each endpoint were
significantly smaller among placebo- versus tolterodine
ER-treated subjects, relationships among endpoints were
generally similar in the active and placebo groups. This is
not unexpected because the correlations should be similar
for changes from baseline that are in the same direction,
whether they occur in the treatment or placebo group.
The current analysis suggests that PROs are relevant and
complementary to changes in UUI episodes in the assess-
ment of OAB treatment; however, the study has some lim-
itations. Inclusion criteria for this study required subjects
to have UUI; therefore, the analysis is limited to only
patients with UUI. However, a large proportion of
patients with OAB are not incontinent [3-5]. Because UUI
was the only variable used to assess these relationships,
we cannot extrapolate these results to other OAB symp-
toms.
Conclusion
Changes in UUI episodes were correlated with changes in
PPBC and HRQL scores in subjects with OAB treated with
either tolterodine ER or placebo. These findings indicate
that data obtained from PROs provide a distinct source of
information about treatment efficacy in the evaluation of
OAB treatments.
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